{"cursor":"65030","size":15,"audio":[],"currentlang":"en","article":"This is a 'list of therapeutic, diagnostic and preventive [[monoclonal\nantibodies]]', antibodies which are clones of a single parent cell. When used as\ndrugs, the International Nonproprietary Names (INNs) end in -mab. The remaining\nsyllables of the INNs, as well as the column Source, are explained in\n[[Nomenclature of monoclonal antibodies]].\n\n\nThe abbreviations in the column Type are as follows:\n\n* mab: whole monoclonal antibody\n* Fab: fragment, antigen-binding (one arm) ** F(ab') 2: fragment, antigen-\n  binding, including hinge region (both arms) ** Fab': fragment, antigen-\n  binding, including hinge region (one arm)\n* Variable fragments: ** scFv: single-chain variable fragment ** di-scFv:\n  dimeric single-chain variable fragment ** sdAb: single-domain antibody\n* Bispecific monoclonal antibodies: ** 3funct: trifunctional antibody ** BiTE:\n  bi-specific T-cell engager\n\nThis list includes approved and investigational drugs as well as drugs that have\nbeen withdrawn from market; consequently, the column Use does not necessarily\nindicate clinical usage.\n\n{| class=\"sortable wikitable\"\n ! Name !! Trade name !! Type !! Source !! Target !! Use\n |- 3F8 || || mab || mouse || GD2 || neuroblastoma - 8H9 ||\n ||| mab || mouse || B7-H3 || neuroblastoma, sarcoma, metastatic brain cancers -\n |Abagovomab || || mab || mouse || CA-125 (imitation) ||\n |ovarian cancer - Abciximab || ReoPro || Fab || chimeric || CD41 (integrin alpha-\n |IIb) || platelet aggregation inhibitor - Actoxumab || ||\n |mab || human || [[Clostridium difficile]] || [[Clostridium difficile]]\n |infection - Adalimumab || Humira || mab || human || TNF-Î± || Rheumatoid\n |arthritis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing\n |Spondylitis, Juvenile Idiopathic Arthritis - Adecatumumab || || mab || human || EpCAM || prostate and breast cancer - Afelimomab ||\n ||| F(ab') 2 || mouse || TNF-Î± || sepsis - Afutuzumab || || mab || humanized || CD20 || lymphoma - Alacizumab\n |pegol || || F(ab') 2 || humanized || VEGFR2 ||\n |cancer - ALD518 || || ? || humanized || IL-6 ||\n |rheumatoid arthritis - Alemtuzumab || Campath,\n |MabCampath || mab || humanized || CD52 || CLL, CTCL - Alirocumab || || mab || human || NARP-1 || hypercholesterolemia -\n |Altumomab pentetate || Hybri-ceaker || mab || mouse || CEA || colorectal\n |cancer (diagnosis) - Amatuximab || || mab || chimeric\n ||| mesothelin || cancer - Anatumomab mafenatox || || Fab || mouse || TAG-72 ||\n |non-small cell lung carcinoma - Anrukinzumab (= IMA-\n |638) || || mab || humanized || IL-13 || ? -\n |Apolizumab || || mab || humanized || HLA-DR ? ||\n |hematological cancers - Arcitumomab || CEA-Scan || Fab' || mouse || CEA ||\n |gastrointestinal cancers (diagnosis) - Aselizumab || ||\n |mab || humanized || L-selectin (CD62L) || severely injured patients -\n |Atinumab || || mab || human || RTN4 || ? - Atlizumab (=\n |tocilizumab) || Actemra, RoActemra || mab || humanized || IL-6 receptor ||\n |rheumatoid arthritis - Atorolimumab || || mab || human || Rhesus factor ||\n |hemolytic disease of the newborn - Bapineuzumab || ||\n |mab || humanized || beta amyloid || Alzheimer's disease - Basiliximab ||\n |Simulect || mab || chimeric || CD25 (Î± chain of IL-2 receptor) || prevention\n |of organ transplant rejections - Bavituximab || || mab\n ||| chimeric || phosphatidylserine || cancer, viral infections - Bectumomab ||\n |LymphoScan || Fab' || mouse || CD22 || non-Hodgkin's lymphoma (detection) -\n |Belimumab || Benlysta, LymphoStat-B || mab || human || BAFF || non-Hodgkin\n |lymphoma etc. - Benralizumab || || mab || humanized || CD125 || asthma -\n |Bertilimumab || || mab || human || CCL11 (eotaxin-1) ||\n |severe allergic disorders - Besilesomab || Scintimun ||\n |mab || mouse || CEA-related antigen || inflammatory lesions and metastases\n |(detection) - Bevacizumab || Avastin || mab || humanized\n ||| VEGF-A || metastatic cancer - Bezlotoxumab || ||\n |mab || human || [[Clostridium difficile]] || [[Clostridium difficile]]\n |infection - Biciromab || FibriScint || Fab' || mouse || fibrin II, beta chain\n ||| thromboembolism (diagnosis) - Bimagrumab || || mab\n ||| human || ACVR2B || myostatin inhibitor - Bivatuzumab mertansine || || mab\n ||| humanized || CD44 v6 || squamous cell carcinoma - Blinatumomab || || BiTE\n ||| mouse || CD19 || cancer - Blosozumab || || mab ||\n |humanized || SOST || osteoporosis - Brentuximab vedotin || || mab || chimeric || CD30 (TNFRSF8) || hematologic cancers -\n |Briakinumab || || mab || human || IL-12, IL-23 ||\n |psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple\n |sclerosis - Brodalumab || || mab || human || IL-17 ||\n |inflammatory diseases - Canakinumab || Ilaris || mab ||\n |human || IL-1? || rheumatoid arthritis - Cantuzumab mertansine || || mab ||\n |humanized || mucin CanAg || colorectal cancer etc. - Cantuzumab ravtansine || || mab || humanized || MUC1 || cancers -\n |Caplacizumab || || mab || humanized || VWF || ? -\n |Capromab pendetide || Prostascint || mab || mouse || prostatic carcinoma cells\n ||| prostate cancer (detection) - Carlumab || || mab ||\n |human || MCP-1 || oncology/immune indications - Catumaxomab || Removab || 3funct || rat/mouse hybrid || EpCAM, CD3 || ovarian cancer,\n |malignant ascites, gastric cancer - CC49 || || mab || mouse || TAG-72 || tumor\n |detection - Cedelizumab || || mab || humanized || CD4 || prevention of organ\n |transplant rejections, treatment of autoimmune diseases - Certolizumab\n |pegol || Cimzia || Fab' || humanized || TNF-Î± || Crohn's\n |disease - Cetuximab || Erbitux || mab || chimeric || EGFR || metastatic\n |colorectal cancer and head and neck cancer - Ch.14.18  || ||\n |mab || chimeric || ??? || neuroblastoma - Citatuzumab bogatox || || Fab || humanized || EpCAM || ovarian cancer and other\n |solid tumors - Cixutumumab || || mab || human || IGF-1 receptor || solid\n |tumors - Clazakizumab || || mab || humanized ||\n |Oryctolagus cuniculus || rheumatoid arthritis - Clenoliximab || || mab ||\n |chimeric || CD4 || rheumatoid arthritis - Clivatuzumab tetraxetan || hPAM4-Cide || mab || humanized || MUC1 ||\n |pancreatic cancer - Conatumumab || || mab || human ||\n |TRAIL-R2 || cancer - Concizumab || || mab || humanized\n ||| TFPI || bleeding - Crenezumab || || mab ||\n |humanized || 1-40-Î²-amyloid || Alzheimer's disease - CR6261 || || mab || human\n ||| Influenza A hemagglutinin || infectious disease/influenza A -\n |Dacetuzumab || || mab || humanized || CD40 ||\n |hematologic cancers - Daclizumab || Zenapax || mab || humanized || CD25 (Î±\n |chain of IL-2 receptor) || prevention of organ transplant rejections -\n |Dalotuzumab || || mab || humanized || insulin-like\n |growth factor I receptor || cancer etc. - Daratumumab\n ||| || mab || human || CD38 (cyclic ADP ribose hydrolase) || ? - Demcizumab || || mab || humanized || DLL4 || cancer - Denosumab || Prolia || mab || human || RANKL || osteoporosis, bone\n |metastases etc. - Detumomab || || mab || mouse || B-lymphoma cell || lymphoma\n |- Dorlimomab aritox || || F(ab') 2 || mouse ||\n |? || ? - Drozitumab || || mab || human || DR5 || cancer\n |etc. - Duligotumab || || mab || human || HER3 || ? -\n |Dupilumab || || mab || human || IL4 || atopic diseases -\n |Dusigitumab || || mab || human || ILGF2 || cancer -\n |Ecromeximab || || mab || chimeric || GD3 ganglioside ||\n |malignant melanoma - Eculizumab || Soliris || mab ||\n |humanized || C5 || paroxysmal nocturnal hemoglobinuria - Edobacomab || || mab\n ||| mouse || endotoxin || sepsis caused by Gram-negative bacteria - Edrecolomab\n ||| Panorex || mab || mouse || EpCAM || colorectal carcinoma - Efalizumab || Raptiva || mab || humanized || LFA-1 (CD11a) || psoriasis\n |(blocks T-cell migration) - Efungumab || Mycograb ||\n |scFv || human || Hsp90 || invasive ''Candida'' infection - Eldelumab || || mab || human || interferon gamma-induced protein ||\n |Crohn's disease, ulcerative colitis - Elotuzumab || || mab || humanized ||\n |SLAMF7 || multiple myeloma - Elsilimomab || || mab || mouse || IL-6 || ? -\n |Enavatuzumab || || mab || humanized || TWEAK receptor\n ||| cancer etc. - Enlimomab pegol || || mab || mouse ||\n |ICAM-1 (CD54) || ? - Enokizumab || || mab || humanized\n ||| IL9 || asthma - Enoticumab || || mab || human ||\n |DLL4 || ? - Ensituximab || || mab || chimeric || 5AC\n ||| cancer - Epitumomab cituxetan || || mab || mouse ||\n |episialin || ? - Epratuzumab || || mab || humanized || CD22 || cancer, SLE -\n |Erlizumab || || F(ab') 2 || humanized || ITGB2\n |(CD18) || heart attack, stroke, traumatic shock - Ertumaxomab || Rexomun || 3funct || rat/mouse hybrid || HER2/neu, CD3 ||\n |breast cancer etc. - Etaracizumab || Abegrin || mab || humanized || integrin\n |Î± vÎ² 3 || melanoma, prostate cancer, ovarian cancer etc. -\n |Etrolizumab || || mab || humanized || integrin\n |Î± 7 Î² 7 || inflammatory bowel disease - Evolocumab || || mab || human || PCSK9 || hypocholesterolemia -\n |Exbivirumab || || mab || human || hepatitis B surface\n |antigen || hepatitis B - Fanolesomab || NeutroSpec || mab\n ||| mouse || CD15 || appendicitis (diagnosis) - Faralimomab || || mab || mouse\n ||| interferon receptor || ? - Farletuzumab || || mab || humanized || folate\n |receptor 1 || ovarian cancer - Fasinumab || || mab ||\n |human || HNGF || ? - FBTA05 || Lymphomun || 3funct ||\n |rat/mouse hybrid || CD20 || chronic lymphocytic leukaemia - Felvizumab || ||\n |mab || humanized || respiratory syncytial virus || respiratory syncytial virus\n |infection - Fezakinumab || || mab || human || IL-22 || rheumatoid arthritis,\n |psoriasis - Ficlatuzumab || || mab || humanized ||\n |HGF || cancer etc. - Figitumumab || || mab || human || IGF-1 receptor ||\n |adrenocortical carcinoma, non-small cell lung carcinoma etc. - Flanvotumab || || mab || human || glycoprotein 75 || melanoma -\n |Fontolizumab || HuZAF || mab || humanized || IFN-Î³ ||\n |Crohn's disease etc. - Foralumab || || mab || human ||\n |CD3 epsilon || ? - Foravirumab || || mab || human ||\n |rabies virus glycoprotein || rabies (prophylaxis) - Fresolimumab || || mab || human || TGF-Î² || idiopathic pulmonary\n |fibrosis, focal segmental glomerulosclerosis, cancer - Fulranumab || || mab || human || NGF || pain - Futuximab || || mab || chimeric || EGFR || ? - Galiximab || || mab ||\n |chimeric || CD80 || B-cell lymphoma - Ganitumab || ||\n |mab || human || IGF-I || cancer - Gantenerumab || || mab\n ||| human || beta amyloid || Alzheimer's disease - Gavilimomab || || mab || mouse || CD147 (basigin) || graft versus host\n |disease - Gemtuzumab ozogamicin || Mylotarg || mab || humanized || CD33 ||\n |acute myelogenous leukemia - Gevokizumab || || mab ||\n |humanized || IL-1Î² || diabetes etc. - Girentuximab ||\n |Rencarex || mab || chimeric || carbonic anhydrase 9 (CA-IX)|| clear cell renal\n |cell carcinoma http://www.prnewswire.com/news-releases/prometheus-obtains-\n |exclusive-us-commercialization-rights-for-rencarex-121075044.html -\n |Glembatumumab vedotin || ||\n |mab || human || GPNMB || melanoma, breast cancer - Golimumab || Simponi || mab || human || TNF-Î± || rheumatoid arthritis,\n |psoriatic arthritis, ankylosing spondylitis - Gomiliximab || || mab ||\n |chimeric || CD23 (IgE receptor) || allergic asthma - GS6624 \n ||| || mab || ? || ? || idiopathic pulmonary fibrosis and solid tumors -\n |Guselkumab || || mab || human || IL13 || psoriasis -\n |Ibalizumab || || mab || humanized || CD4 || HIV\n |infection - Ibritumomab tiuxetan || Zevalin || mab || mouse || CD20 || non-\n |Hodgkin's lymphoma - Icrucumab || || mab || human || VEGFR-\n |1 || cancer etc. - Igovomab || Indimacis-125 || F(ab') 2 || mouse ||\n |CA-125 || ovarian cancer (diagnosis) - Imciromab || Myoscint || mab || mouse\n ||| cardiac myosin || cardiac imaging - Imgatuzumab ||\n ||| mab || humanized || EGFR || cancer - Inclacumab ||\n ||| mab || human || selectin P || ? - Indatuximab ravtansine || || mab || chimeric || SDC1 || cancer - Infliximab ||\n |Remicade || mab || chimeric || TNF-Î± || rheumatoid arthritis, ankylosing\n |spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative\n |colitis - Intetumumab || || mab || human || CD51 || solid tumors (prostate\n |cancer, melanoma) - Inolimomab || || mab || mouse || CD25 (Î± chain of IL-2\n |receptor) || graft versus host disease - Inotuzumab ozogamicin || || mab || humanized || CD22 || cancer - Ipilimumab || Yervoy || mab || human || CD152 || melanoma -\n |Iratumumab || || mab || human || CD30 (TNFRSF8) ||\n |Hodgkin's lymphoma - Itolizumab || || mab || humanized\n ||| CD6 || ? - Ixekizumab || || mab || humanized || IL-\n |17A || autoimmune diseases - Keliximab || || mab || chimeric || CD4 || chronic\n |asthma - Labetuzumab || CEA-Cide || mab || humanized ||\n |CEA || colorectal cancer - Lampalizumab || || mab ||\n |humanized || CFD || ? - Lebrikizumab || || mab ||\n |humanized || IL-13 || asthma - Lemalesomab || || mab ||\n |mouse || NCA-90 (granulocyte antigen) || diagnostic agent - Lerdelimumab || || mab || human || TGF beta 2 || reduction of scarring\n |after glaucoma surgery - Lexatumumab || || mab || human\n ||| TRAIL-R2 || cancer - Libivirumab || || mab || human\n ||| hepatitis B surface antigen || hepatitis B - Ligelizumab || || mab || humanized || IGHE || ? - Lintuzumab || || mab\n ||| humanized || CD33 || cancer - Lirilumab || || mab ||\n |human || KIR2D || ? - Lodelcizumab || || mab ||\n |humanized || PCSK9 || hypercholesterolemia - Lorvotuzumab mertansine || || mab\n ||| humanized || CD56 || cancer - Lucatumumab || || mab\n ||| human || CD40 || multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's\n |lymphoma - Lumiliximab || || mab || chimeric || CD23\n |(IgE receptor) || chronic lymphocytic leukemia - Mapatumumab || || mab || human || TRAIL-R1 || cancer - Margetuximab || || mab || humanized || ch4D5 || cancer - Maslimomab ||\n ||| ? || mouse || T-cell receptor || ? - Mavrilimumab\n ||| || mab || human || GMCSF receptor Î±-chain || rheumatoid arthritis -\n |Matuzumab || || mab || humanized || EGFR || colorectal,\n |lung and stomach cancer - Mepolizumab || Bosatria || mab || humanized || IL-5\n ||| asthma and white blood cell diseases - Metelimumab ||\n ||| mab || human || TGF beta 1 || systemic scleroderma - Milatuzumab || || mab || humanized || CD74 || multiple myeloma and other\n |hematological malignancies - Minretumomab || || mab || mouse || TAG-72 || ? -\n |Mitumomab || || mab || mouse || GD3 ganglioside || small cell lung carcinoma -\n |Mogamulizumab || || mab || humanized || CCR4 ||\n |cancer - Morolimumab || || mab || human || Rhesus factor || ? -\n |Motavizumab || Numax || mab || humanized || respiratory\n |syncytial virus || respiratory syncytial virus (prevention) - Moxetumomab\n |pasudotox || || mab || mouse || CD22 ||\n |cancer - Muromonab-CD3 || Orthoclone OKT3 || mab || mouse || CD3 || prevention\n |of organ transplant rejections - Nacolomab tafenatox || || Fab || mouse ||\n |C242 antigen || colorectal cancer - Namilumab || || mab\n ||| human || CSF2 || ? - Naptumomab estafenatox || || Fab\n ||| mouse || 5T4 || non-small cell lung carcinoma, renal cell carcinoma -\n |Narnatumab || || mab || human || RON || cancer -\n |Natalizumab || Tysabri || mab || humanized || integrin Î± 4 ||\n |multiple sclerosis, Crohn's disease - Nebacumab || || mab || human ||\n |endotoxin || sepsis - Necitumumab || || mab || human ||\n |EGFR || non-small cell lung carcinoma - Nerelimomab || || mab || mouse || TNF-\n |Î± || ? - Nesvacumab || || mab || human || angiopoietin\n |2 || cancer - Nimotuzumab ||\n |Theracim, Theraloc || mab || humanized || EGFR || squamous cell carcinoma,\n |head and neck cancer, nasopharyngeal cancer, glioma - Nivolumab || || mab || human || IgG4 || cancer - Nofetumomab merpentan\n ||| Verluma || Fab || mouse || ? || cancer (diagnosis) - Ocaratuzumab || || mab || humanized || CD20 || cancer - Ocrelizumab || || mab || humanized || CD20 || rheumatoid arthritis,\n |lupus erythematosus etc. - Odulimomab || || mab || mouse || LFA-1 (CD11a) ||\n |prevention of organ transplant rejections, immunological diseases -\n |Ofatumumab || Arzerra || mab || human || CD20 || chronic\n |lymphocytic leukemia etc. - Olaratumab || || mab || human || PDGF-R Î± ||\n |cancer - Olokizumab || || mab || humanized || IL6 || ?\n |- Omalizumab || Xolair || mab || humanized || IgE Fc\n |region || allergic asthma - Onartuzumab || || mab ||\n |humanized || human scatter factor receptor kinase || cancer - Oportuzumab\n |monatox || || scFv || humanized || EpCAM || cancer -\n |Oregovomab || OvaRex || mab || mouse || CA-125 ||\n |ovarian cancer - Orticumab || || mab || human || oxLDL\n ||| ? - Otelixizumab || || mab || chimeric/humanized ||\n |CD3 || diabetes mellitus type 1 - Oxelumab || || mab ||\n |human || OX-40 || asthma - Ozanezumab || || mab ||\n |humanized || NOGO-A || ALS and multiple sclerosis - Ozoralizumab || || mab || humanized || [[Lama glama]] || inflammation\n |- Pagibaximab || || mab || chimeric || lipoteichoic acid\n ||| sepsis ([[Staphylococcus]]) - Palivizumab || Synagis, Abbosynagis || mab ||\n |humanized || F protein of respiratory syncytial virus || respiratory syncytial\n |virus (prevention) - Panitumumab || Vectibix || mab ||\n |human || EGFR || colorectal cancer - Panobacumab || ||\n |mab || human || [[Pseudomonas aeruginosa]] || Pseudomonas aeruginosa infection\n |- Parsatuzumab || || mab || human || EGFL7 || cancer -\n |Pascolizumab || || mab || humanized || IL-4 || asthma -\n |Pateclizumab || || mab || humanized || LTA || TNF -\n |Patritumab || || mab || human || HER3 || cancer -\n |Pemtumomab || Theragyn || ? || mouse || MUC1 || cancer - Perakizumab || || mab || humanized || IL17A || ? - Pertuzumab ||\n |Omnitarg || mab || humanized || HER2/neu || cancer - Pexelizumab || || scFv || humanized || C5 || reduction of side effects\n |of cardiac surgery - Pidilizumab || || mab ||\n |humanized || PD-1 || cancer and infectious diseases - Pinatuzumab vedotin || || mab || humanized || CD22 || cancer - Pintumomab || ||\n |mab || mouse || adenocarcinoma antigen || adenocarcinoma (imaging) -\n |Placulumab || || mab || human || human TNF || ? -\n |Polatuzumab vedotin || || mab || humanized || CD79B ||\n |? - Ponezumab || || mab || humanized ||human beta-\n |amyloid || Alzheimer's disease - Priliximab || || mab || chimeric || CD4 ||\n |Crohn's disease, multiple sclerosis - Pritoxaximab ||\n ||| mab || chimeric || [[Escherichia coli|E. coli]] shiga toxin type-1 || ? -\n |Pritumumab || || mab || human || vimentin || brain cancer - PRO 140 || || ? ||\n |humanized || CCR5 || HIV infection - Quilizumab || ||\n |mab || humanized || IGHE || ? - Racotumomab || || mab\n ||| mouse || N-glycolylneuraminic acid || cancer - Radretumab || || mab || human || fibronectin extra domain-B || cancer\n |- Rafivirumab || || mab || human || rabies virus\n |glycoprotein || rabies (prophylaxis) - Ramucirumab || || mab || human ||\n |VEGFR2 || solid tumors - Ranibizumab || Lucentis || Fab\n ||| humanized || VEGF-A || macular degeneration (wet form) - Raxibacumab || || mab || human || anthrax toxin, protective antigen ||\n |anthrax (prophylaxis and treatment) - Regavirumab || || mab || human ||\n |cytomegalovirus glycoprotein B || cytomegalovirus infection - Reslizumab || || mab || humanized || IL-5 || inflammations of the\n |airways, skin and gastrointestinal tract - Rilotumumab\n ||| || mab || human || HGF || solid tumors - Rituximab || MabThera, Rituxan ||\n |mab || chimeric || CD20 || lymphomas, leukemias, some autoimmune disorders -\n |Robatumumab || || mab || human || IGF-1 receptor || cancer - Roledumab || || mab || human || RHD || ? - Romosozumab || || mab || humanized || scleroscin || osteoporosis -\n |Rontalizumab || || mab || humanized || IFN-Î± ||\n |systemic lupus erythematosus - Rovelizumab || LeukArrest || mab || humanized\n ||| CD11, CD18 || haemorrhagic shock etc. - Ruplizumab ||\n |Antova || mab || humanized || CD154 (CD40L) || rheumatic diseases -\n |Samalizumab || || mab || humanized || CD200 || cancer\n |- Sarilumab || || mab || human || IL6 || rheumatoid\n |arthritis, ankylosing spondylitis - Satumomab pendetide || || mab || mouse ||\n |TAG-72 || cancer (diagnosis) - Secukinumab || || mab\n ||| human || IL-17A || uveitis, rheumatoid arthritis psoriasis -\n |Seribantumab || || mab || human || ERBB3 || cancer -\n |Setoxaximab || || mab || chimeric || [[Escherichia\n |coli|E. coli]] shiga toxin type-1 || ? - Sevirumab || || ? || human ||\n |cytomegalovirus || cytomegalovirus infection - Sibrotuzumab || || mab ||\n |humanized || FAP || cancer - Sifalimumab || || mab ||\n |humanized || IFN-Î± || SLE, dermatomyositis, polymyositis - Siltuximab || ||\n |mab || chimeric || IL-6 || cancer - Simtuzumab || ||\n |mab || humanized || LOXL2 || ? - Siplizumab || || mab ||\n |humanized || CD2 || psoriasis, graft-versus-host disease (prevention) -\n |Sirukumab || || mab || human || IL-6 || rheumatoid\n |arthritis - Solanezumab || || mab || humanized || beta\n |amyloid || Alzheimer's disease - Solitomab || || mab ||\n |mouse || EpCAM || ? - Sonepcizumab || || ? || humanized || sphingosine-1-\n |phosphate || choroidal and retinal neovascularization - Sontuzumab || || mab || humanized || episialin || ? - Stamulumab || || mab || human || myostatin ||\n |muscular dystrophy - Sulesomab || LeukoScan || Fab' || mouse || NCA-90\n |(granulocyte antigen) || osteomyelitis (imaging) - Suvizumab || || mab || humanized || HIV-1 || viral infections -\n |Tabalumab || || mab || human || BAFF || B-cell cancers -\n |Tacatuzumab tetraxetan || AFP-Cide || mab || humanized || alpha-fetoprotein ||\n |cancer - Tadocizumab || || Fab || humanized || integrin\n |Î± IIb Î² 3 || percutaneous coronary intervention - Talizumab\n ||| || mab || humanized || IgE || allergic reaction - Tanezumab || || mab || humanized || NGF || pain - Taplitumomab\n |paptox || || mab || mouse || CD19 || cancer -\n |Tefibazumab || Aurexis || mab || humanized || clumping\n |factor A || [[Staphylococcus aureus]] infection - Telimomab aritox || || Fab\n ||| mouse || ? || ? - Tenatumomab || || mab || mouse ||\n |tenascin C || cancer - Teneliximab || || mab || chimeric\n ||| CD40 || ? - Teplizumab || || mab || humanized || CD3\n ||| diabetes mellitus type 1 - Teprotumumab || || mab\n ||| human || CD221 || hematologic tumors - TGN1412 || || ? || humanized || CD28\n ||| chronic lymphocytic leukemia, rheumatoid arthritis - Ticilimumab (=\n |tremelimumab) || || mab || human || CTLA-4 || cancer - Tildrakizumab || || mab || humanized || IL23 || immunologically\n |mediated inflammatory disorders - Tigatuzumab || || mab\n ||| humanized || TRAIL-R2 || cancer - TNX-650 || || ? || humanized || IL-13 ||\n |Hodgkin's lymphoma - Tocilizumab (= atlizumab) ||\n |Actemra, RoActemra || mab || humanized || IL-6 receptor || rheumatoid\n |arthritis - Toralizumab || || mab || humanized || CD154\n |(CD40L) || rheumatoid arthritis, lupus nephritis etc. - Tositumomab || Bexxar\n ||| ? || mouse || CD20 || follicular lymphoma - Tovetumab\n ||| || mab || human || CD140a || cancer - Tralokinumab\n ||| || mab || human || IL-13 || asthma etc. - Trastuzumab || Herceptin || mab\n ||| humanized || HER2/neu || breast cancer - TRBS07 || Ektomab ||\n |3funct || ? || GD2 || melanoma - Tregalizumab || || mab\n ||| humanized || CD4 || ? - Tremelimumab || || mab || human || CTLA-4 || cancer\n |- Tucotuzumab celmoleukin || ||\n |mab || humanized || EpCAM || cancer - Tuvirumab || || ? || human || hepatitis\n |B virus || chronic hepatitis B - Ublituximab || || mab\n ||| chimeric || MS4A1 || cancer - Urelumab || || mab ||\n |human || 4-1BB || cancer etc. - Urtoxazumab || || mab ||\n |humanized || [[Escherichia coli]] || diarrhoea caused by E. coli -\n |Ustekinumab || Stelara || mab || human || IL-12, IL-23\n ||| multiple sclerosis, psoriasis, psoriatic arthritis - Vantictumab || || mab || human || Frizzled receptor || cancer -\n |Vapaliximab || || mab || chimeric || AOC3 (VAP-1) || ? -\n |Vatelizumab || || mab || humanized || ITGA2 || ? -\n |Vedolizumab || || mab || humanized || integrin Î± 4Î² 7 ||\n |Crohn's disease, ulcerative colitis - Veltuzumab || ||\n |mab || humanized || CD20 || non-Hodgkin's lymphoma - Vepalimomab || || mab ||\n |mouse || AOC3 (VAP-1) || inflammation - Vesencumab ||\n ||| mab || human || NRP1 || ? - Visilizumab || Nuvion ||\n |mab || humanized || CD3 || Crohn's disease, ulcerative colitis -\n |Volociximab || || mab || chimeric || integrin\n |Î± 5Î² 1 || solid tumors - Vorsetuzumab mafodotin || || mab || humanized || CD70 || cancer -\n |Votumumab || HumaSPECT || mab || human || tumor antigen CTAA16.88 ||\n |colorectal tumors - Zalutumumab || HuMax-EGFr || mab ||\n |human || EGFR || squamous cell carcinoma of the head and neck -\n |Zanolimumab || HuMax-CD4 || mab || human || CD4 ||\n |rheumatoid arthritis, psoriasis, T-cell lymphoma - Zatuximab || || mab || chimeric || HER1 || cancer - Ziralimumab || || mab || human || CD147 (basigin) || ? - Zolimomab\n |aritox || || mab || mouse || CD5 || systemic lupus erythematosus, graft-versus-\n |host disease }\n","linknr":1971,"url":"List_of_monoclonal_antibodies","recorded":1362901838,"links":218,"instances":["111in_altumomab_pentetate","protein","gene","influenza","gene","99mtc_nofetumomab_merpentan","immunology"],"pdf":["http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf","http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf","http://www.ama-assn.org/resources/doc/usan/actoxumab.pdf","http://www.ama-assn.org/resources/doc/usan/actoxumab.pdf","http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf","http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf","http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf","http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf","http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf","http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf","http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf","http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf","http://www.ama-assn.org/resources/doc/usan/alirocumab.pdf","http://www.ama-assn.org/resources/doc/usan/alirocumab.pdf","http://www.ama-assn.org/resources/doc/usan/amatuximab.pdf","http://www.ama-assn.org/resources/doc/usan/amatuximab.pdf","http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf","http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf","http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf","http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf","http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf","http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf","http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf","http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf","http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf","http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf","http://www.ama-assn.org/resources/doc/usan/bezlotoxumab.pdf","http://www.ama-assn.org/resources/doc/usan/bezlotoxumab.pdf","http://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf","http://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf","http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf","http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf","http://www.ama-assn.org/resources/doc/usan/brodalumab.pdf","http://www.ama-assn.org/resources/doc/usan/brodalumab.pdf","http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf","http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf","http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf","http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf","http://www.ama-assn.org/resources/doc/usan/carlumab.pdf","http://www.ama-assn.org/resources/doc/usan/carlumab.pdf","http://www.ama-assn.org/resources/doc/usan/clazakizumab.pdf","http://www.ama-assn.org/resources/doc/usan/clazakizumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf","http://www.ama-assn.org/resources/doc/usan/crenezumab.pdf","http://www.ama-assn.org/resources/doc/usan/crenezumab.pdf","http://www.ama-assn.org/resources/doc/usan/dalotuzumab.pdf","http://www.ama-assn.org/resources/doc/usan/dalotuzumab.pdf","http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf","http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf","http://www.ama-assn.org/resources/doc/usan/demcizumab.pdf","http://www.ama-assn.org/resources/doc/usan/demcizumab.pdf","http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf","http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf","http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf","http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf","http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf","http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf","http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf","http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf","http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf","http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf","http://www.ama-assn.org/resources/doc/usan/dusigitumab.pdf","http://www.ama-assn.org/resources/doc/usan/dusigitumab.pdf","http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf","http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf","http://www.ama-assn.org/resources/doc/usan/eldelumab.pdf","http://www.ama-assn.org/resources/doc/usan/eldelumab.pdf","http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf","http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf","http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf","http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf","http://www.ama-assn.org/resources/doc/usan/enokizumab.pdf","http://www.ama-assn.org/resources/doc/usan/enokizumab.pdf","http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf","http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf","http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf","http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf","http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf","http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf","http://www.ama-assn.org/resources/doc/usan/etrolizumab.pdf","http://www.ama-assn.org/resources/doc/usan/etrolizumab.pdf","http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf","http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf","http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf","http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf","http://www.ama-assn.org/resources/doc/usan/fasinumab.pdf","http://www.ama-assn.org/resources/doc/usan/fasinumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf","http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf","http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf","http://www.ama-assn.org/resources/doc/usan/flanvotumab.pdf","http://www.ama-assn.org/resources/doc/usan/flanvotumab.pdf","http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf","http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf","http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf","http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf","http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf","http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf","http://www.ama-assn.org/resources/doc/usan/gevokizumab.pdf","http://www.ama-assn.org/resources/doc/usan/gevokizumab.pdf","http://www.who.int/medicines/services/inn/FINAL_PL102.pdf","http://www.who.int/medicines/services/inn/FINAL_PL102.pdf","http://www.ama-assn.org/resources/doc/usan/guselkumab.pdf","http://www.ama-assn.org/resources/doc/usan/guselkumab.pdf","http://www.ama-assn.org/resources/doc/usan/icrucumab.pdf","http://www.ama-assn.org/resources/doc/usan/icrucumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf","http://www.ama-assn.org/resources/doc/usan/ixekizumab.pdf","http://www.ama-assn.org/resources/doc/usan/ixekizumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf","http://www.ama-assn.org/resources/doc/usan/margetuximab.pdf","http://www.ama-assn.org/resources/doc/usan/margetuximab.pdf","http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf","http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf","http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf","http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf","http://www.ama-assn.org/resources/doc/usan/moxetumomab-pasudotox.pdf","http://www.ama-assn.org/resources/doc/usan/moxetumomab-pasudotox.pdf","http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf","http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf","http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf","http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf","http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf","http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf","http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf","http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf","http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf","http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf","http://www.ama-assn.org/resources/doc/usan/nivolumab.pdf","http://www.ama-assn.org/resources/doc/usan/nivolumab.pdf","http://www.ama-assn.org/resources/doc/usan/ocaratuzumab.pdf","http://www.ama-assn.org/resources/doc/usan/ocaratuzumab.pdf","http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf","http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf","http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf","http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf","http://www.ama-assn.org/resources/doc/usan/ozanezumab.pdf","http://www.ama-assn.org/resources/doc/usan/ozanezumab.pdf","http://www.ama-assn.org/resources/doc/usan/ozoralizumab.pdf","http://www.ama-assn.org/resources/doc/usan/ozoralizumab.pdf","http://www.ama-assn.org/resources/doc/usan/pidilizumab.pdf","http://www.ama-assn.org/resources/doc/usan/pidilizumab.pdf","http://www.ama-assn.org/resources/doc/usan/placulumab.pdf","http://www.ama-assn.org/resources/doc/usan/placulumab.pdf","http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf","http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf","http://www.ama-assn.org/resources/doc/usan/romosozumab.pdf","http://www.ama-assn.org/resources/doc/usan/romosozumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf","http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf","http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/sarilumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/sarilumab.pdf","http://www.ama-assn.org/resources/doc/usan/secukinumab.pdf","http://www.ama-assn.org/resources/doc/usan/secukinumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf","http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf","http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf","http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf","http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf","http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf","http://www.ama-assn.org/resources/doc/usan/teprotumumab.pdf","http://www.ama-assn.org/resources/doc/usan/teprotumumab.pdf","http://www.ama-assn.org/resources/doc/usan/tildrakizumab.pdf","http://www.ama-assn.org/resources/doc/usan/tildrakizumab.pdf","http://www.ama-assn.org/resources/doc/usan/tovetumab.pdf","http://www.ama-assn.org/resources/doc/usan/tovetumab.pdf","http://www.ama-assn.org/resources/doc/usan/tralokinumab.pdf","http://www.ama-assn.org/resources/doc/usan/tralokinumab.pdf","http://www.ama-assn.org/resources/doc/usan/urelumab.pdf","http://www.ama-assn.org/resources/doc/usan/urelumab.pdf","http://www.ama-assn.org/resources/doc/usan/vantictumab.pdf","http://www.ama-assn.org/resources/doc/usan/vantictumab.pdf","http://www.ama-assn.org/resources/doc/usan/vorsetuzumab_mafodotin.pdf","http://www.ama-assn.org/resources/doc/usan/vorsetuzumab_mafodotin.pdf"],"categories":["Drug-related lists|Monoclonal Antibodies","Monoclonal antibodies|"],"headings":["References"],"image":["//upload.wikimedia.org/wikipedia/commons/thumb/2/2e/Engineered_monoclonal_antibodies.svg/400px-Engineered_monoclonal_antibodies.svg.png","//bits.wikimedia.org/static-1.21wmf10/skins/common/images/magnify-clip.png","//upload.wikimedia.org/wikipedia/commons/thumb/2/2e/Engineered_monoclonal_antibodies.svg/200px-Engineered_monoclonal_antibodies.svg.png","//bits.wikimedia.org/static-1.21wmf10/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.21wmf10/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[["indium","111in_altumomab_pentetate"],["cd3","immunology"],["hemagglutinin","influenza"],["cd3","immunology"],["technetium","99mtc_fanolesomab"],["cd3","immunology"],["technetium","99mtc_nofetumomab_merpentan"],["cd3","immunology"],["rhd","gene"],["fap","gene"],["cd3","immunology"],["cd3","immunology"],["cd5","protein"]],"members":["indium","cd5","fap","hemagglutinin","rhd","technetium","cd3"],"related":["International_Nonproprietary_Name","Fragment_antigen-binding","Variable_fragment","Single-chain_variable_fragment","Single-domain_antibody","Bispecific_monoclonal_antibodies","Trifunctional_antibody","Bi-specific_T-cell_engager","Approved_drug","Investigational_drug","3F8","GD2","Neuroblastoma","8H9","B7-H3","Abagovomab","CA-125","Ovarian_cancer","Abciximab","CD41","Platelet_aggregation_inhibitor","Actoxumab","Adalimumab","TNF-α","Rheumatoid_arthritis","Crohn's_Disease","Psoriasis","Psoriatic_Arthritis","Ankylosing_Spondylitis","Juvenile_Idiopathic_Arthritis","Adecatumumab","EpCAM","Prostate_cancer","Breast_cancer","Afelimomab","TNF-α","Sepsis","Afutuzumab","CD20","Lymphoma","Alacizumab_pegol","VEGFR2","Cancer","ALD518","Interleukin_6","Alemtuzumab","CD52","Chronic_lymphocytic_leukemia","Cutaneous_T_cell_lymphoma","Alirocumab","Hypercholesterolemia","Indium_(111In)_altumomab_pentetate","Carcinoembryonic_antigen","Amatuximab","Mesothelin","Anatumomab_mafenatox","Tumor-associated_glycoprotein_72","Non-small_cell_lung_carcinoma","Anrukinzumab","Interleukin_13","Apolizumab","HLA-DR","Hematological_cancer","Arcitumomab","Carcinoembryonic_antigen","Aselizumab","L-selectin","Atinumab","RTN4","Atlizumab","IL-6_receptor","Atorolimumab","Rhesus_factor","Hemolytic_disease_of_the_newborn","Bapineuzumab","Beta_amyloid","Alzheimer's_disease","Basiliximab","CD25","Interleukin_2","Transplant_rejection","Bavituximab","Phosphatidylserine","Bectumomab","CD22","Non-Hodgkin's_lymphoma","Belimumab","B-cell_activating_factor","Benralizumab","CD125","Bertilimumab","CCL11","Besilesomab","Carcinoembryonic_antigen","Bevacizumab","Vascular_endothelial_growth_factor_A","Bezlotoxumab","Biciromab","Fibrin","Thromboembolism","Bimagrumab","ACVR2B","Myostatin","Bivatuzumab_mertansine","CD44","Squamous_cell_carcinoma","Blinatumomab","CD19","Blosozumab","SOST","Brentuximab_vedotin","CD30","Briakinumab","Interleukin-12","Interleukin-23","Psoriasis","Rheumatoid_arthritis","Inflammatory_bowel_disease","Multiple_sclerosis","Brodalumab","Interleukin-17","Canakinumab","Interleukin_1","Cantuzumab_mertansine","Mucin","Cantuzumab_ravtansine","Caplacizumab","Capromab_pendetide","Carlumab","MCP-1","Catumaxomab","EpCAM","CD3_(immunology)","Ascites","CC49","Tumor-associated_glycoprotein_72","Cedelizumab","CD4","Certolizumab_pegol","TNF-α","Crohn's_disease","Cetuximab","Epidermal_growth_factor_receptor","Colorectal_cancer","Head_and_neck_cancer","Ch.14.18","Neuroblastoma","Citatuzumab_bogatox","EpCAM","Cixutumumab","IGF-1_receptor","Clazakizumab","Clenoliximab","CD4","Clivatuzumab_tetraxetan","MUC1","Pancreatic_cancer","Conatumumab","TRAIL-R2","Concizumab","Tissue_factor_pathway_inhibitor","Bleeding","Crenezumab","1-40-beta-amyloid","Alzheimer's_disease","CR6261","Hemagglutinin_(influenza)","Dacetuzumab","CD40","Daclizumab","CD25","Interleukin_2","Dalotuzumab","Daratumumab","CD38","Demcizumab","Denosumab","RANKL","Osteoporosis","Detumomab","Dorlimomab_aritox","Drozitumab","TNFRSF10B","Duligotumab","HER3","Dupilumab","Interleukin_4","Dusigitumab","Insulin-like_growth_factor_II","Ecromeximab","Ganglioside","Eculizumab","Complement_component_5","Paroxysmal_nocturnal_hemoglobinuria","Edobacomab","Endotoxin","Gram-negative","Edrecolomab","EpCAM","Efalizumab","LFA-1","CD11a","Psoriasis","T-cell","Efungumab","Hsp90","Candidiasis","Eldelumab","Interferon","Crohn's_disease","Ulcerative_colitis","Elotuzumab","SLAMF7","Multiple_myeloma","Elsilimomab","Interleukin_6","Enavatuzumab","TWEAK_receptor","Enlimomab_pegol","ICAM-1","Enokizumab","Interleukin_9","Asthma","Enoticumab","DLL4","Ensituximab","5AC","Epitumomab_cituxetan","Epratuzumab","CD22","Systemic_lupus_erythematosus","Erlizumab","ITGB2","Heart_attack","Stroke","Traumatic_shock","Ertumaxomab","HER2/neu","CD3_(immunology)","Etaracizumab","Integrin","Alpha-v_beta-3","Prostate_cancer","Ovarian_cancer","Etrolizumab","Integrin","Alpha-7_beta-7","Inflammatory_bowel_disease","Evolocumab","PCSK9","Hypocholesterolemia","Exbivirumab","Hepatitis_B","Technetium_(99mTc)_fanolesomab","CD15","Appendicitis","Faralimomab","Interferon_receptor","Farletuzumab","Folate_receptor_1","Fasinumab","Nerve_growth_factor","FBTA05","CD20","Chronic_lymphocytic_leukaemia","Felvizumab","Respiratory_syncytial_virus","Fezakinumab","Interleukin_22","Psoriasis","Ficlatuzumab","Hepatocyte_growth_factor","Figitumumab","IGF-1_receptor","Adrenocortical_carcinoma","Non-small_cell_lung_carcinoma","Flanvotumab","Glycoprotein_75","Fontolizumab","IFN-γ","Foralumab","CD3_epsilon","Foravirumab","Rabies","Fresolimumab","TGF-β","Idiopathic_pulmonary_fibrosis","Focal_segmental_glomerulosclerosis","Fulranumab","Nerve_growth_factor","Futuximab","Epidermal_growth_factor_receptor","Galiximab","CD80","B-cell_lymphoma","Ganitumab","IGF-I","Gantenerumab","Beta_amyloid","Gavilimomab","CD147","Graft_versus_host_disease","Gemtuzumab_ozogamicin","CD33","Acute_myelogenous_leukemia","Gevokizumab","IL-1β","Diabetes","Girentuximab","Carbonic_anhydrase_9","Renal_cell_carcinoma","Glembatumumab_vedotin","GPNMB","Golimumab","TNF-α","Gomiliximab","CD23","IgE_receptor","Allergic_asthma","GS6624","Pulmonary_fibrosis","Guselkumab","Interleukin_13","Psoriasis","Ibalizumab","CD4","HIV_infection","Ibritumomab_tiuxetan","CD20","Icrucumab","VEGFR-1","Igovomab","CA-125","Imciromab","Cardiac","Myosin","Cardiac","Imgatuzumab","Epidermal_growth_factor_receptor","Inclacumab","Indatuximab_ravtansine","SDC1","Infliximab","TNF-α","Intetumumab","CD51","Inolimomab","CD25","Interleukin_2","Inotuzumab_ozogamicin","CD22","Ipilimumab","CD152","Melanoma","Iratumumab","CD30","Hodgkin's_lymphoma","Itolizumab","CD6","Ixekizumab","IL-17A","Keliximab","CD4","Labetuzumab","Carcinoembryonic_antigen","Colorectal_cancer","Lampalizumab","Complement_factor_D","Lebrikizumab","Interleukin_13","Asthma","Lemalesomab","Lerdelimumab","TGF_beta_2","Glaucoma_surgery","Lexatumumab","TRAIL-R2","Libivirumab","Hepatitis_B","Ligelizumab","IGHE","Lintuzumab","CD33","Lirilumab","KIR2D","Lodelcizumab","PCSK9","Hypercholesterolemia","Lorvotuzumab_mertansine","CD56","Lucatumumab","CD40","Multiple_myeloma","Non-Hodgkin's_lymphoma","Hodgkin's_lymphoma","Lumiliximab","CD23","IgE_receptor","Chronic_lymphocytic_leukemia","Mapatumumab","TRAIL","Margetuximab","Ch4D5","Maslimomab","Mavrilimumab","GMCSF_receptor_alpha-chain","Rheumatoid_arthritis","Matuzumab","Epidermal_growth_factor_receptor","Mepolizumab","Interleukin_5","Metelimumab","TGF_beta_1","Systemic_scleroderma","Milatuzumab","CD74","Minretumomab","Tumor-associated_glycoprotein_72","Mitumomab","Ganglioside","Small_cell_lung_carcinoma","Mogamulizumab","CCR4","Morolimumab","Rhesus_factor","Motavizumab","Respiratory_syncytial_virus","Moxetumomab_pasudotox","CD22","Muromonab-CD3","CD3_(immunology)","Nacolomab_tafenatox","Namilumab","CSF2","Naptumomab_estafenatox","5T4","Renal_cell_carcinoma","Narnatumab","Natalizumab","Integrin","Multiple_sclerosis","Nebacumab","Endotoxin","Necitumumab","Epidermal_growth_factor_receptor","Nerelimomab","TNF-α","Nesvacumab","Angiopoietin_2","Nimotuzumab","Epidermal_growth_factor_receptor","Nasopharyngeal_cancer","Glioma","Nivolumab","Technetium_(99mTc)_nofetumomab_merpentan","Ocaratuzumab","CD20","Ocrelizumab","CD20","Odulimomab","LFA-1","CD11a","Ofatumumab","CD20","Olaratumab","Platelet-derived_growth_factor_receptor_alpha","Olokizumab","Interleukin_6","Omalizumab","IgE","Fc_region","Onartuzumab","Oportuzumab_monatox","EpCAM","Oregovomab","CA-125","Orticumab","Oxidized_low-density_lipoprotein","Otelixizumab","CD3_(immunology)","Oxelumab","OX-40","Ozanezumab","Multiple_sclerosis","Ozoralizumab","Pagibaximab","Lipoteichoic_acid","Palivizumab","Respiratory_syncytial_virus","Panitumumab","Epidermal_growth_factor_receptor","Panobacumab","Parsatuzumab","EGFL7","Pascolizumab","Interleukin_4","Pateclizumab","Lymphotoxin_alpha","TNF","Patritumab","HER3","Pemtumomab","MUC1","Perakizumab","IL17A","Pertuzumab","HER2/neu","Pexelizumab","Complement_component_5","Cardiac_surgery","Pidilizumab","Pinatuzumab_vedotin","CD22","Pintumomab","Adenocarcinoma","Adenocarcinoma","Placulumab","Polatuzumab_vedotin","CD79B","Ponezumab","Beta-amyloid","Priliximab","CD4","Pritoxaximab","Shiga_toxin","Pritumumab","Vimentin","Brain_cancer","PRO_140","CCR5","Quilizumab","Racotumomab","Glycolylneuraminic_acid","Radretumab","Fibronectin","Rafivirumab","Rabies","Ramucirumab","VEGFR2","Ranibizumab","VEGF-A","Macular_degeneration","Raxibacumab","Anthrax","Regavirumab","Cytomegalovirus","Reslizumab","Interleukin_5","Inflammation","Rilotumumab","Hepatocyte_growth_factor","Rituximab","CD20","Leukemia","Robatumumab","IGF-1_receptor","Roledumab","RHD_(gene)","Romosozumab","Scleroscin","Osteoporosis","Rontalizumab","Interferon-alpha","Systemic_lupus_erythematosus","Rovelizumab","CD11","CD18","Haemorrhagic_shock","Ruplizumab","CD154","Samalizumab","CD200","Sarilumab","Interleukin_6","Ankylosing_spondylitis","Satumomab_pendetide","Tumor-associated_glycoprotein_72","Secukinumab","IL-17A","Uveitis","Psoriasis","Seribantumab","ERBB3","Setoxaximab","Shiga_toxin","Sevirumab","Cytomegalovirus","Sibrotuzumab","FAP_(gene)","Sifalimumab","Interferon-alpha","Systemic_lupus_erythematosus","Dermatomyositis","Polymyositis","Siltuximab","Interleukin-6","Simtuzumab","LOXL2","Siplizumab","CD2","Graft-versus-host_disease","Sirukumab","Interleukin_6","Solanezumab","Beta_amyloid","Solitomab","EpCAM","Sonepcizumab","Sphingosine-1-phosphate","Choroidal_neovascularization","Retina","Neovascularization","Sontuzumab","Stamulumab","Myostatin","Sulesomab","Osteomyelitis","Suvizumab","HIV-1","Tabalumab","B-cell_activating_factor","Tacatuzumab_tetraxetan","Alpha-fetoprotein","Tadocizumab","Integrin","Percutaneous_coronary_intervention","Talizumab","IgE","Allergic_reaction","Tanezumab","Nerve_growth_factor","Pain","Taplitumomab_paptox","CD19","Tefibazumab","Clumping_factor_A","Telimomab_aritox","Tenatumomab","Tenascin_C","Teneliximab","CD40","Teplizumab","CD3_(immunology)","Diabetes_mellitus_type_1","Teprotumumab","CD221","TGN1412","CD28","Ticilimumab","CTLA-4","Tildrakizumab","Interleukin_23","Tigatuzumab","TRAIL-R2","TNX-650","Interleukin_13","Tocilizumab","IL-6_receptor","Toralizumab","CD154","Tositumomab","CD20","Follicular_lymphoma","Tovetumab","CD140a","Tralokinumab","Interleukin_13","Trastuzumab","HER2/neu","Breast_cancer","TRBS07","Tregalizumab","CD4","Tremelimumab","CTLA-4","Tucotuzumab_celmoleukin","EpCAM","Tuvirumab","Hepatitis_B","Ublituximab","MS4A1","Urelumab","4-1BB","Urtoxazumab","Ustekinumab","Interleukin_12","Interleukin_23","Vantictumab","Frizzled_receptor","Vapaliximab","AOC3","Vatelizumab","ITGA2","Vedolizumab","Integrin","Ulcerative_colitis","Veltuzumab","CD20","Vepalimomab","AOC3","Vesencumab","NRP1","Visilizumab","CD3_(immunology)","Volociximab","Integrin","Vorsetuzumab_mafodotin","CD70","Votumumab","Tumor_antigen","Zalutumumab","Epidermal_growth_factor_receptor","Squamous_cell_carcinoma_of_the_head_and_neck","Zanolimumab","CD4","Zatuximab","HER1","Ziralimumab","CD147","Zolimomab_aritox","CD5_(protein)","Wyeth","National_Cancer_Institute"]}